Topic resource collection
Approved comparison material connected to this topic.
6 resourcesRead both sides
CJC-1295/Ipamorelin Stimulates pulsatile GH secretion; improves lipolysis and lean mass retention 200–300mcg each, 3–5×/week subcutaneous Body composition changes visible at 8–12 weeks; metabolic markers improve at 4–6 weeks Mode…
GLP-1 Agonists (Semaglutide, Tirzepatide) Delays gastric emptying, reduces ghrelin rebound, improves insulin sensitivity 0.25mg-2.4mg weekly (titrated over 16-20 weeks) Appetite suppression in 3-7 days; measurable fat loss by wee…
Before selecting a peptide protocol, compare mechanisms, administration logistics, and clinical endpoints relevant to postmenopausal physiology. BPC-157 VEGF upregulation, collagen synthesis Daily subcutaneous (250–500mcg) 18% in…
BPC-157 VEGF upregulation, angiogenesis acceleration Tendon/ligament repair, gut healing, systemic anti-inflammatory 250–500 mcg daily Subcutaneous injection near injury site or systemic Gold standard for soft tissue recovery in …
Women over 40 have more delivery options than most peptide guides acknowledge. The choice depends on your primary goal, comfort with injections, and desired systemic versus local effects. 1-2% serum (skin-specific) 1-2 mg SC (sys…
Perimenopause and post-menopause present different challenges. The peptide priorities shift as hormonal status changes. Estrogen status Fluctuating, declining Low, stable Primary skin concern Early collagen loss Advanced collagen…